Want to see MGNX full AI Analyst Report?
MGNX Stock Chart & Stats
$3.46
-$0.07(-2.05%)
At close: 4:00 PM EST
$3.46
-$0.07(-2.05%)
Day’s Range― - ―
52-Week Range$1.29 - $5.08
Previous CloseN/A
Volume157.79K
Average Volume (3M)1.13M
Market Cap
$285.40M
Enterprise Value$134.36
Total Cash (Recent Filing)$154.23M
Total Debt (Recent Filing)$36.51M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,563,120
10 Day Avg. Volume883,882
30 Day Avg. Volume1,134,082
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.33Price Target Upside83.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$136.26M
Bulls Say, Bears Say
Bulls Say
High Gross Margin On Recurring RevenueSustained ~63% gross margin on $157.1M TTM revenue indicates the core antibody development business generates meaningful gross profit per dollar of sales. That margin profile supports R&D funding capacity and partnerships long-term, even if operating losses persist, improving runway options over months.
Non-dilutive Royalty Financing ExpandedThe $130M aggregate royalty financing provides non-dilutive liquidity that materially improves near-term funding flexibility. Because it preserves upside tied to ZYNYZ milestones, the structure supports pipeline funding without immediate equity issuance, reducing dilution risk while maintaining long-term upside alignment.
Shift To Asset-light R&D Model After Asset SaleSelling manufacturing assets and outsourcing production to Bora converts fixed-capital burden into variable supply agreements, lowering ongoing capex and operational complexity. This asset-light pivot preserves capital for clinical programs and can sustainably reduce cash burn and operational risk over multiple quarters.
Bears Say
Large Operating Cash BurnPersistent negative operating and free cash flow (~-$70M TTM) signals ongoing funding needs and reliance on external financing or asset monetization. Over 2–6 months this structural burn rate pressures liquidity and forces strategic financing choices that could dilute equity or constrain program spending if not offset by deals.
Leverage And Thin Equity BaseElevated debt-to-equity with a small equity base reduces financial flexibility and raises refinancing and dilution risk. With limited equity cushion, adverse trial outcomes or slower milestone receipts could compel costly financing or equity issuance, affecting long-term capital structure and strategic optionality over upcoming quarters.
Persistent Operating LossesDeep and persistent operating losses (≈-45% net margin) reflect a cost base exceeding current revenue. Unless clinical programs yield near-term milestones or commercialization, negative profitability will continue to erode resources and necessitate financing or asset sales, constraining sustained R&D investment and growth execution.
MacroGenics News
MGNX FAQ
What was MacroGenics Inc’s price range in the past 12 months?
MacroGenics Inc lowest stock price was $1.29 and its highest was $5.08 in the past 12 months.
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is $285.40M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 23 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on May 13, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.574 by -$0.006.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is 0.03.
How many shares outstanding does MacroGenics Inc have?
MacroGenics Inc has 63,563,120 shares outstanding.
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.574. Following the earnings report the stock price went up 20.58%.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in MGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (83.04% Upside)
$6.33 (83.04% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
191.55%
12-Months-Change
Fundamentals
Return on Equity
-147.80%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Stock 12 Month Forecast
Average Price Target
$6.33
▲(83.04% Upside)
Technical Analysis
Ownership Overview
2.59% Insiders
12.16% Mutual Funds
3.18% Other Institutional Investors
72.44% Public Companies and
Individual Investors